Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996);Estudio comparativo de piperacilina/tazobactam frente a imipenem/cilastatina en la neutropenia febril (1994-1996)

Medicina Clinica

Volumn 116, Issue 16, 2001, Pages 610-611

  Figuera, Ángela ^a   Rivero, Natividad ^b   Pajuelo, Francisco ^a   Font, Patricia ^a   Leyra, Fernando ^a   De la Caómara, Rafael ^a   Arranz, Reyes ^a   Fernaóndez Ranãada, José María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Departamento Cientifico de Wyeht Lederle   (Spain)

Author keywords

Febrile neutropenia; Imipenem cilastatin; Monotherapy; Piperacillin tazobactam

Indexed keywords

CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEVER; HUMAN; MAJOR CLINICAL STUDY; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 0035810522     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)71921-5     Document Type: Article

References (10)

1. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
2. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient
3. In vitro activity of piperacillin-tazobactam against 365 aerobic bacteria isolated from blood in granulocytopenic cancer patients
4. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
5. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients
6. Beta-lactam/beta-lactamase inhibitor combinations: Pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host
7. A national multicenter study of the in vitro activity of piperacilin-tazobactam
8. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
9. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies
10. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients